The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis

被引:26
作者
Perez-Casal, Margarita [1 ]
Thompson, Victoria [3 ]
Downey, Colin [1 ]
Welters, Ingeborg [3 ]
Wyncoll, Duncan [4 ]
Thachil, Jecko [1 ,3 ]
Toh, Cheng Hock [1 ,2 ,3 ]
机构
[1] Royal Liverpool Univ Hosp, Roald Dahl Haemostasis & Thrombosis Ctr, Liverpool L7 8XP, Merseyside, England
[2] Royal Liverpool Univ Hosp, Natl Inst Hlth Res Biomed Res Ctr, Liverpool L7 8XP, Merseyside, England
[3] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Univ Clin Dept, Liverpool L693GA, Merseyside, England
[4] Guys & St Thomas NHS Fdn Trust, St Thomass Hosp, Crit Care Unit, London SE1 7EH, England
来源
CRITICAL CARE | 2011年 / 15卷 / 04期
基金
英国惠康基金; 英国医学研究理事会;
关键词
ENDOTHELIAL-CELLS; CIRCULATING MICROPARTICLES; TISSUE FACTOR; ORGAN DYSFUNCTION; CELLULAR-ORIGIN; SEPTIC SHOCK; RECEPTOR; GENERATION; IDENTIFICATION; COAGULATION;
D O I
10.1186/cc10356
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Activated protein C (APC) induces release of microparticles (MP) from primary physiological cells, which are found in patients undergoing treatment with recombinant human APC (rhAPC) for severe sepsis. We hypothesised that APC on these circulating MPs activate endothelial protease-activated receptor 1 (PAR1) to induce anti-apoptotic and anti-inflammatory properties that can improve patient outcome. Methods: This was an experimental study on clinical samples in an intensive care setting, and included patients with severe sepsis who fulfilled criteria for treatment with rhAPC. The number of CD13+ MPs from the patients were analysed to determine their origin. They were also quantified for endothelial protein C receptor (EPCR) and APC expression. Clinical relevance of these MPs were ascertained by comparing survival between the group receiving rhAPC (n = 25) and a control group of untreated patients (n = 25). MPs were also incubated with endothelial cells to analyse apoptotic gene expression, cytoprotection and anti-inflammatory effects. Results: rhAPC treatment induced a significant increase in circulating MP-associated EPCR by flow cytometry (P < 0.05) and by quantitative ELISA (P < 0.005). APC expression also showed significant increases (P < 0.05). Numerically, CD13+ MPs were higher in rhAPC-treated survivors versus non-survivors. However, the number of non-survivors was low and this was not significantly different. APC on MPs was demonstrated to induce antiapoptotic and endothelial barrier effects through the activation of endothelial PAR1. Conclusions: rhAPC treatment in patients with sepsis significantly increases circulating EPCR + MPs. These MPs were noted to express APC, which has specific anti-apoptotic and anti-inflammatory effects, with a non-significant correlative trend towards survival. This suggests that MPs could disseminate APC function and activate endothelial PAR1 at distal vascular sites.
引用
收藏
页数:11
相关论文
共 48 条
[1]   Enclothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome [J].
Agouni, Abdelali ;
Lagrue-Lak-Hal, Anne Helene ;
Ducluzeau, Pierre Henri ;
Mostefai, Hadj Ahmed ;
Draunet-Busson, Catherine ;
Leftheriotis, Georges ;
Heymes, Christophe ;
Martinez, Maria Carmen ;
Andriantsitohaina, Ramaroson .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (04) :1210-1219
[2]   Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia [J].
Aras, O ;
Shet, A ;
Bach, RR ;
Hysjulien, JL ;
Slungaard, A ;
Hebbel, RP ;
Escolar, G ;
Jilma, B ;
Key, NS .
BLOOD, 2004, 103 (12) :4545-4553
[3]   The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a banier-protective response in endothelial cells [J].
Bae, Jong-Sup ;
Yang, Likui ;
Manithody, Chandrashekhara ;
Rezaie, Alireza R. .
BLOOD, 2007, 110 (12) :3909-3916
[4]  
Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]   Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction [J].
Boulanger, CM ;
Scoazec, A ;
Ebrahimian, T ;
Henry, P ;
Mathieu, E ;
Tedgui, A ;
Mallat, Z .
CIRCULATION, 2001, 104 (22) :2649-2652
[8]   Minimum information about a microarray experiment (MIAME) - toward standards for microarray data [J].
Brazma, A ;
Hingamp, P ;
Quackenbush, J ;
Sherlock, G ;
Spellman, P ;
Stoeckert, C ;
Aach, J ;
Ansorge, W ;
Ball, CA ;
Causton, HC ;
Gaasterland, T ;
Glenisson, P ;
Holstege, FCP ;
Kim, IF ;
Markowitz, V ;
Matese, JC ;
Parkinson, H ;
Robinson, A ;
Sarkans, U ;
Schulze-Kremer, S ;
Stewart, J ;
Taylor, R ;
Vilo, J ;
Vingron, M .
NATURE GENETICS, 2001, 29 (04) :365-371
[9]   In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant [J].
Combes, V ;
Simon, AC ;
Grau, GE ;
Arnoux, D ;
Camoin, L ;
Sabatier, F ;
Mutin, M ;
Sanmarco, M ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :93-102
[10]   Microparticles in type 2 diabetes mellitus [J].
Davi, G ;
Ferroni, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (06) :1166-1167